Solid tumor CAR-T therapy / Anixa Biosci, Moffitt Cancer Center - LARVOL DELTA

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology (PRNewswire) - "Anixa Biosciences...announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Number 12,384,826 covering its chimeric antigen receptor-T cell (CAR-T) technology. This new patent extends protection of Anixa's CAR-T technology to 2045....Anixa's CAR-T technology is currently in a clinical trial at Moffitt Cancer Center, treating recurrent ovarian cancer patients."

Patent • Ovarian Cancer

IL-18R equipped CAR T cells against oncofetal Tenascin C for pediatric solid and brain tumor immunotherapy (SITC 2024) - "Background A critical limitation for solid tumor CAR T cell therapy is the lack of safe, targetable antigens...Although C.TNC-CAR T cell antitumor efficacy is transient, transgenic expression of Zip18R bolsters their antitumor activity to confer a significant survival advantage. Thus, C.TNC-CAR.Zip18R T cells warrant further exploration for the immunotherapy of solid and brain tumors expressing C.TNC."

CAR T-Cell Therapy • Clinical • IO biomarker • Brain Cancer • Glioma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • IFNG • IL18

An NGS assay to identify HLA loss of heterozygosity for future CEA and MSLN logic-gated CAR-T solid tumor protocols designed for reduced on-target, off-tumor toxicity (SITC 2022) - P=N/A | "6 Tempus xT-Onco reliably detects HLA LOH and quantifies CEA and MSLN expression. Based on these data, patients with solid tumors are now being prospectively screened for HLA LOH using xT-Onco in an ongoing tissue banking study (BASECAMP-1, NCT04981119 ), preparing for future interventional protocols."

Clinical • IO biomarker • Next-generation sequencing • Hematological Malignancies • Oncology • Solid Tumor • CEACAM5 • HLA-A • MSI • MSLN • TMB

Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy Technology (Anixa Biosciences Press Release) - "Anixa Biosciences, Inc...announced...that the China National Intellectual Property Administration (CNIPA) has issued a Notification of Grant of Patent Right on Anixa's novel Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology, known as its Chimeric Endocrine Receptor T-cell, or CER-T approach, or more specifically, 'Follicle Stimulating Hormone Receptor-Mediated CAR-T technology,' which has been licensed from The Wistar Institute and is being developed in partnership with Moffitt Cancer Center."

Patent • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy (PRNewswire) - "Anixa Biosciences, Inc...announced...that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa's novel Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology, known as its Chimeric Endocrine Receptor T-cell, or CER-T approach, or more specifically, 'Follicle Stimulating Hormone Receptor-Mediated CAR-T technology,' which has been licensed from The Wistar Institute and is being developed in partnership with Moffitt Cancer Center.....'This technology takes advantage of specific hormone-to-hormone receptor biology to address malignancies and holds promise to be the first successful CAR-T therapy against solid tumors. While our initial focus is the treatment of ovarian cancer—with clinical trials expected to begin before year-end—the technology covered by the patent is broad and may have applicability in treating other solid tumors by exploiting an anti-angiogenesis mechanism of action.'"

New trial • Patent • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor